| Business Summary | | Paradigm
Genetics,
Inc.
has
industrialized
the
process
of
determining
gene
function
to
generate
information
that
it
believes
will
enable
it
and
its
commercial
partners
to
develop
novel
products
in
four
major
sectors
of
the
global
economy:
human
health,
nutrition,
crop
production,
and
industrial
products.
The
Company
has
developed
an
industrialized,
high
throughput
platform,
known
as
the
GeneFunction
Factory,
which
is
capable
of
determining
the
function
of
over
a
hundred
plant
and
microbial
genes
per
week.
The
Company
is
able
to
determine
gene
function
at
a
rate
far
greater
than
that
achieved
historically.
The
Company
believes
this
gives
it
an
advantage
in
establishing
intellectual
property
and
developing
new
products. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Paradigm
Genetics
is
industrializing
the
process
of
determining
gene
function
by
creating
an
assembly
line
process
to
generate
information
to
enable
the
development
of
novel
products
in
the
crop,
nutrition,
human
health
and
industrial
markets.
For
the
six
months
ended
6/30/01,
revenues
totaled
$11.5
million,
up
from
$2.3
million.
Net
loss
applicable
to
Common
fell
61%
to
$8.3
million.
Results
reflect
revenues
from
the
Bayer
partnership,
partially
offset
by
higher
R&D
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| G. Steven Burrill, 56 Chairman | -- | John Ryals, Ph.D., 47 Pres,
CEO, Director | $378K | Ian Howes, 42 VP-
Fin. and Operations, CFO, Treasurer | 234K | Henry Nowak, 45 VP
of Intellectual Property, Gen. Counsel, Sec. | -- | James Bucci, 56 VP
of HR | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|